Additionally, the anti-CC chemokine receptor 4 (CCR4) antibody KW-0761 is undergoing a phase II clinical trial to assess efficacy, safety, and pharmacokinetic profiles in CCR4-positive adult T-cell leukemia/lymphoma [49]. The gene discussed is CCR4; the disease is lymphoma.